Completed PHASE2 INTERVENTIONAL 2-arm NCT04463004

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation

Sponsor: Kiniksa Pharmaceuticals, Ltd.

Conditions COVID-19 Pneumonia Sars-CoV2

Interventions Mavrilimumab Placebos

Updated 9 times since 2020 Last updated: Aug 4, 2021 Started: Sep 2, 2020 Primary completion: Nov 30, 2020 Completion: Nov 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates COVID-19 and Pneumonia and is currently completed. Kiniksa Pharmaceuticals, Ltd. leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Sep 2021 — Dec 2022 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed

▶ Show 4 earlier versions

Mar 2021 — Sep 2021 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jan 2021 — Mar 2021 [monthly]

Recruiting PHASE2
Oct 2020 — Jan 2021 [monthly]

Recruiting PHASE2
Aug 2020 — Oct 2020 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kiniksa Pharmaceuticals, Ltd.
Virginia Commonwealth University

Data source: Virginia Commonwealth University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Richmond, United States